Advicenne: Evolution of governance and challenges ahead

Advicenne, a pharmaceutical company specializing in rare kidney diseases, announces changes to its governance following its Combined General Meeting on May 21, 2026. This meeting approved various resolutions concerning the company's financial statements and the allocation of financial and share-based compensation. New appointments were made, notably André Ulmann and Adrian Hepner as directors for three-year terms.

The board of directors also welcomes Didier Laurens as chairman, while Charlotte Sibley takes the helm of the compensation committee. Adrian Hepner, with his extensive expertise, will strengthen the company's US focus. Finally, Advicenne is concentrating on advancing the drug Sibnayal® in the United States and on a critical financial restructuring.